Here’s a bold statement: one healthcare company’s stock might be hiding a golden opportunity right under investors’ noses. But here’s where it gets controversial—while many have written it off, Macquarie believes Ebos Group Ltd (ASX: EBO) is severely undervalued, and its upcoming earnings results could be a game-changer. If you’re a long-suffering shareholder, this might just be the news you’ve been waiting for.
Before diving in, remember: this is a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Curious about what our top analysts are recommending? Become a Motley Fool member today for instant access to in-depth research and more.
Ebos Group, a company with a diversified portfolio spanning human and animal healthcare, has seen its shares trading at $22.30—hovering near their 12-month low of $21.61 and a far cry from their peak of $38.23. And this is the part most people miss: despite a tumble after last year’s full-year results, the company’s fundamentals remain strong, according to Macquarie. So, what’s the real story here?
At the company’s annual general meeting in late October, Chair Elizabeth Coutts shed light on the situation. She emphasized that Ebos operates in attractive markets with supportive megatrends across both healthcare and animal care segments. However, she didn’t sugarcoat the challenges: ‘We are operating in an environment influenced by near-term macro pressures which we do need to work through.’
Here’s where it gets interesting: Coutts highlighted Ebos’s leadership as a pharmaceutical wholesaler in Australia and New Zealand, as well as its position as one of the largest healthcare-focused contract logistics providers in the region. In animal care, the company boasts the largest dry dog food brand by volume in the pet specialty category. Impressive, right?
But here’s the controversial part: while FY25 delivered solid results, Coutts warned that the current financial year will be a ‘year of transition’ as the company navigates macro pressures. Yet, she remains optimistic about the future, pointing to disciplined investments and operational efficiencies that will position Ebos for long-term growth. By FY27, the benefits of their distribution centre renewal program are expected to shine through.
Macquarie’s take? They believe Ebos is well-placed to surprise the market. In a recent research note ahead of the company’s February 25 results, Macquarie’s analyst team noted that risks are ‘skewed to the upside,’ with benefits from distribution centre investments expected to materialize in the current half year. Their price target? A whopping NZ$39.78 ($34.16) for the dual-listed shares, coupled with a 5% dividend yield, translating to a potential total shareholder return of 60.5%.
Now, here’s a thought-provoking question: Is the market overlooking Ebos’s long-term potential due to short-term pressures? Or is Macquarie’s optimism misplaced? Let us know your thoughts in the comments below.
For more insights on healthcare shares, check out these articles:
- Why this beaten-down ASX 200 healthcare stock could rebound 66%
- 3 reasons to buy CSL shares today
Remember, this service provides general financial advice only and does not consider your personal circumstances. Investments can go up and down, and past performance is not indicative of future returns. For more information, see our Financial Services Guide.
We acknowledge the Traditional Custodians of the land where we live and work, and pay our respects to all Elders, past and present, of all Aboriginal and Torres Strait Islander nations.
© 2010 - 2026 The Motley Fool Australia Pty Ltd. All rights reserved. ACN: 146 988 052 | AFSL: 400691 | Contact: (03) 8592 4841 | Email
